{"id":"comirnaty-omicron-xbb-1-5","safety":{"commonSideEffects":[{"rate":"~70%","effect":"Injection site pain"},{"rate":"~60%","effect":"Fatigue"},{"rate":"~55%","effect":"Headache"},{"rate":"~40%","effect":"Myalgia"},{"rate":"~15%","effect":"Fever"},{"rate":"~10%","effect":"Chills"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine delivers lipid nanoparticle-encapsulated mRNA encoding the spike protein of the XBB.1.5 Omicron subvariant. Upon intramuscular injection, the mRNA is translated by host cells to produce the antigen, which stimulates both humoral (antibody) and cellular (T-cell) immune responses. This updated formulation targets circulating Omicron subvariants to enhance protection against infection and severe disease.","oneSentence":"Comirnaty Omicron XBB.1.5 is an mRNA vaccine that instructs cells to produce the spike protein of the XBB.1.5 Omicron variant, triggering immune recognition and antibody production against this SARS-CoV-2 strain.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:30:44.933Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of COVID-19 caused by SARS-CoV-2 (Omicron XBB.1.5 subvariant)"}]},"trialDetails":[{"nctId":"NCT05032976","phase":"","title":"Korea Comirnaty Post-marketing Surveillance","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2022-03-18","conditions":"COVID-19, Vaccines, Adverse Effects","enrollment":12000},{"nctId":"NCT05556720","phase":"PHASE3","title":"Bringing Optimised COVID-19 Vaccine Schedules To ImmunoCompromised Populations (BOOST-IC): an Adaptive Randomised Controlled Clinical Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Monash University","startDate":"2022-12-01","conditions":"HIV, Organ Transplantation, Lymphoma, Non-Hodgkin","enrollment":960},{"nctId":"NCT06452654","phase":"PHASE4","title":"Anti-viral Action Against Type 1 Diabetes Autoimmunity","status":"RECRUITING","sponsor":"Technical University of Munich","startDate":"2024-05-08","conditions":"Diabetes Mellitus, Type 1","enrollment":2252},{"nctId":"NCT06130410","phase":"","title":"Special Investigation for Booster Dose of Comirnaty in Children Ages 6 Months Though 4 Years","status":"COMPLETED","sponsor":"Pfizer","startDate":"2024-03-06","conditions":"SARS-CoV-2, COVID-19","enrollment":25},{"nctId":"NCT05924685","phase":"PHASE4","title":"PREPARE-iVAC Trial","status":"COMPLETED","sponsor":"University Medical Center Groningen","startDate":"2023-08-22","conditions":"COVID-19 Vaccines, Varicella Zoster Vaccine, Vaccine Response","enrollment":110},{"nctId":"NCT05075538","phase":"PHASE4","title":"COVID-19: Immune Response in Patients With Cancer Undergoing mRNA Vaccination Against SARS-CoV-2","status":"TERMINATED","sponsor":"Jules Bordet Institute","startDate":"2021-12-01","conditions":"Cancer","enrollment":152}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Comirnaty Omicron XBB.1.5","genericName":"Comirnaty Omicron XBB.1.5","companyName":"Jules Bordet Institute","companyId":"jules-bordet-institute","modality":"Biologic","firstApprovalDate":"","aiSummary":"Comirnaty Omicron XBB.1.5 is an mRNA vaccine that instructs cells to produce the spike protein of the XBB.1.5 Omicron variant, triggering immune recognition and antibody production against this SARS-CoV-2 strain. Used for Prevention of COVID-19 caused by SARS-CoV-2 (Omicron XBB.1.5 subvariant).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}